Intensivecare
Intensivecare S.p.A. is an innovative start-up specializing in extracorporeal treatments with proprietary technologies, patents, and projects. The company aims to develop minimally invasive, high-impact therapeutic systems that improve patient care and reduce healthcare costs. It is committed to advancing good medical practices through technologically valid and easy-to-use products, with a focus on reducing invasiveness and supporting critical care treatments.
Industries
Nr. of Employees
small (1-50)
Intensivecare
84131 Salerno, Via Terre Delle Risaie 20/A, Italy
Products
Low‑flow veno‑venous extracorporeal CO2 removal system (lung dialysis device)
A minimally invasive medical device system that performs extracorporeal removal of carbon dioxide via veno‑venous access using a double‑lumen catheter, oxygenator and integrated pump and monitoring subsystems to support ventilation strategies.
Low‑flow veno‑venous extracorporeal CO2 removal system (lung dialysis device)
A minimally invasive medical device system that performs extracorporeal removal of carbon dioxide via veno‑venous access using a double‑lumen catheter, oxygenator and integrated pump and monitoring subsystems to support ventilation strategies.
Services
Provides clinical collaboration, investigator engagement and device support for multicenter studies evaluating extracorporeal CO2 removal therapies.
Arranges distribution partnerships and implements industrial plans for market introduction of extracorporeal medical devices.
Provides clinical collaboration, investigator engagement and device support for multicenter studies evaluating extracorporeal CO2 removal therapies.
Arranges distribution partnerships and implements industrial plans for market introduction of extracorporeal medical devices.
Expertise Areas
- Extracorporeal CO2 removal (ECCO2R) and lung dialysis
- Medical device R&D and engineering for extracorporeal systems
- Clinical study collaboration and multicenter trial support
- Critical care respiratory support (ARDS, COPD exacerbations)
Key Technologies
- Extracorporeal CO2 removal (ECCO2R)
- Veno‑venous low‑flow extracorporeal circuits
- Double‑lumen venous catheter access
- Atraumatic single‑roller peristaltic pump design
News & Updates
Confermato il valore di quotazione per Intensivecare Spa
The company confirmed its stock market listing value at over 140 million euros, maintaining its high valuation after listing on the Luxembourg Stock Exchange in May 2020.
Lo studio ORION parte da Salerno
A scientific study called ORION, supported by the company and involving numerous Italian centers, aims to evaluate the effectiveness of extracorporeal CO2 removal in COPD patients, with leading researchers Prof. Marco Ranieri and Prof. Stefano Nava.
Intensivecare Spa si quota in Borsa
The company was officially listed on the Luxembourg Stock Exchange on May 15, with an initial capitalization exceeding 140 million euros, making it one of the few Italian start-ups with such a high valuation.
Area critica 2019
A congress held in Bologna on December 5-6, 2019, focused on clinical-organizational issues and scientific aspects of conditions requiring support and advanced monitoring, where Intensivecare presented its new PneumoHelp device.
Confermato il valore di quotazione per Intensivecare Spa
The company confirmed its stock market listing value at over 140 million euros, maintaining its high valuation after listing on the Luxembourg Stock Exchange in May 2020.
Lo studio ORION parte da Salerno
A scientific study called ORION, supported by the company and involving numerous Italian centers, aims to evaluate the effectiveness of extracorporeal CO2 removal in COPD patients, with leading researchers Prof. Marco Ranieri and Prof. Stefano Nava.
Intensivecare Spa si quota in Borsa
The company was officially listed on the Luxembourg Stock Exchange on May 15, with an initial capitalization exceeding 140 million euros, making it one of the few Italian start-ups with such a high valuation.
Area critica 2019
A congress held in Bologna on December 5-6, 2019, focused on clinical-organizational issues and scientific aspects of conditions requiring support and advanced monitoring, where Intensivecare presented its new PneumoHelp device.